Related references
Note: Only part of the references are listed.DPP-4 inhibition and islet function
Bo Ahren
JOURNAL OF DIABETES INVESTIGATION (2012)
Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes
Daisuke Yabe et al.
JOURNAL OF DIABETES INVESTIGATION (2012)
Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study
Yutaka Seino et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2011)
Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as Isoglycemic Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes
Irfan Vardarli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes
Atsunori Kashiwagi et al.
JOURNAL OF DIABETES INVESTIGATION (2011)
Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus
Akira Kubota et al.
JOURNAL OF DIABETES INVESTIGATION (2011)
Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1
E. M. Migoya et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naive Patients With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2010)
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus
K. Aaboe et al.
DIABETES OBESITY & METABOLISM (2010)
GIP and GLP-1, the two incretin hormones: Similarities and differences
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls
Daisuke Yabe et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Report of the Committee on the classification and diagnostic criteria of diabetes mellitus The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus
Yutaka Seino et al.
DIABETOLOGY INTERNATIONAL (2010)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
Richard E. Pratley et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2009)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
R. E. Pratley et al.
DIABETES OBESITY & METABOLISM (2009)
Hypoglycaemia with Oral Antidiabetic Drugs Results from Prescription-Event Monitoring Cohorts of Rosiglitazone, Pioglitazone, Nateglinide and Repaglinide
Veronika Vlckova et al.
DRUG SAFETY (2009)
STATEMENT BY AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS PANEL ON TYPE 2 DIABETES MELLITUS: AN ALGORITHM FOR GLYCEMIC CONTROL
Helena W. Rodbard et al.
ENDOCRINE PRACTICE (2009)
Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Richard E. Pratley
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
M. A. Nauck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
Joshua J. Neumiller
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2009)
Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice
Nancy Bohannon
POSTGRADUATE MEDICINE (2009)
Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia A nested case-control analysis
Michael Bodmer et al.
DIABETES CARE (2008)
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control A randomized, double-blind, placebo-controlled study
Ralph A. DeFronzo et al.
DIABETES CARE (2008)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes - A population-based study of health service resource use
GP Leese et al.
DIABETES CARE (2003)
Share Paper
